Literature DB >> 34923834

Home direct-to-consumer telehealth solutions for children with mental health disorders and the impact of Covid-19.

Sierra Norman1, Shireen Atabaki2, Kathleen Atmore2, Cara Biddle2, Marc DiFazio2, Daniel Felten2, Eduardo Fox2, Donna Marschall2, Julie Newman2, Adelaide Robb2, Cecilia Rowland2, Rachel Selekman2, Ariella Slovin2, Mark Stein3, John Strang2, Craig Sable2.   

Abstract

Delivery of mental health treatment in the home can close gaps in care. Telehealth also provides access to healthcare that has been disrupted due to the COVID-19 pandemic. In 2016, a home direct-to-consumer telehealth program was initiated. Mental health encounters made up a significant portion of all telehealth encounters and COVID-19 had a significant impact on accelerating the utilization of telehealth. Telemental health has been more successful at meeting targeted volumes than the overall health system. Of all the mental health diagnoses before and during COVID-19, attention deficit hyperactivity disorder, Autism Spectrum Disorder, and Anxiety Disorder were most common. The direct-to-consumer telehealth program saved patients a significant amount of travel miles and associated time, based on data from the period before COVID-19. Payment reimbursement for direct-to-consumer telehealth professional services was similar to reimbursement for in-person visits. This program demonstrates direct-to-consumer telehealth is a feasible and acceptable care modality for a variety of youth mental health disorders.

Entities:  

Keywords:  Covid-19; Telehealth; children; mental health; psychiatry

Mesh:

Year:  2021        PMID: 34923834     DOI: 10.1177/13591045211064134

Source DB:  PubMed          Journal:  Clin Child Psychol Psychiatry        ISSN: 1359-1045            Impact factor:   2.544


  1 in total

1.  Editorial Perspective: COVID-19, ADHD management and telehealth: uncertain path.

Authors:  Mark A Stein
Journal:  J Child Psychol Psychiatry       Date:  2022-02-09       Impact factor: 8.265

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.